ViB's Practical Market Share Forecasting in Pharma

ViB eventsTuesday 24th and Wednesday 25th June 2008, Le Méridien Piccadilly London, UK
Following the success of the Total Market Forecasting conferences, VIB events is now pleased to offer a practical hands-on market share forecasting workshop addressing the specific needs of European pharmaceutical affiliate companies. This practical workshop covers market share forecasting and assumption setting for both in-market and pipeline products.

ViB's Practical Market Share Forecasting in Pharma event will provide the participants with the fundamentals of market share forecasting in a complete market and the opportunity to work with new best-of-breed system applications designed to develop accurate opportunity, volume and cash market share forecasts in a structured centralised IT environment.

Participants are encouraged to bring their own laptops to maximise their involvement in the workshop. So, to ensure you stay on track with latest developments and to network with other professionals in the forecasting area, book your place now.

ViB events only put useful and relevant items on the schedule:

  • Innovative solutions - A ViB conference is a guarantee of meticulous research into the topic.
  • Depth of knowledge - The proposed information products are "narrow and deep" rather than "broad and vague" allowing the event participants to get focused, highly targeted information that adds real value.
  • Tailoring the content to your situation - Whilst the content is "narrow and deep" the proposed "open mic" sessions will allow you to put all the speakers in the hot seat and ask your individual queries.
  • Interaction - Delegates will intermingle as much as possible with the experts: lunch and breaks are devised to facilitate "getting stuck-in" so you can ask the speakers the difficult questions on a one to one basis.
  • Panel discussions - ViB conferences reject the traditional conference format in favour of just sitting you down in small groups with the authorities on the topic so you can hammer out the issues that interest you.
  • Networking – Networking opportunities are more focused towards other like-minded people in smaller forums rather than huge, diffuse gatherings, so you will meet relevant people in your industry that share a common goals and issues.

Simply register now at:
http://www.market-forecasting.com/training
Alternatively download the brochure at:
http://www.market-forecasting.com/training/requestbrochure.htm
For further information, please visit:
http://www.market-forecasting.com/training

About ViB events
ViB events produce a number of high quality, timely and topical conferences, seminars and executive summits. We are committed to delivering high quality, content rich events for a number of industry sectors including Construction, Packaging, Pharmaceuticals, Telecoms, Finance, Transport, Energy and Leadership. For more information, please visit www.vibevents.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...